Drug Search Results
More Filters [+]

Zuclopenthixol

Alternative Names: zuclopenthixol, zuclopentixol
Latest Update: 2024-11-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: D1 Antagonist,D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zuclopenthixol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title